<DOC>
	<DOCNO>NCT01984372</DOCNO>
	<brief_summary>This study conduct Asia . The aim post marketing surveillance ( PMS ) ass safety effectiveness long-term treatment Tresiba® ( insulin degludec ) patient diabetes mellitus require insulin therapy normal clinical practice condition . A total 4000 patient enrol investigate long term ( 3 year treatment ) safety Tresiba® additional 2000 patient enrol assess safety early stage PMS precisely . At time enrolment patient randomly allocate either 3 year 6 month observation group .</brief_summary>
	<brief_title>Post-marketing Surveillance ( Special Use-results Surveillance ) Long-term Use With Tresiba®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Patients diabetes mellitus require insulin therapy treat physician decide start Tresiba® treatment Patients previously Tresiba® therapy Patients previously participate PMS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>